Clormecaine is a local anesthetic drug.

Clotioxone is a fungicide compound for the use in agriculture, developed by a French company Rhone-Poulenc in the 1960s.

Clofurac is an anti-inflammatory compound synthesized by Sandoz in the 1980s. In animal models, clofurac inhibited the acute inflammation induced by carrageenin, was more effective in adjuvant-induced arthritis than diclofenac, and inhibited PGE2 and PGF2a synthesis in vitro. The compound was found to be strongly ulcerogenic in the rat.

Cloprothiazole is a thiazole derivative, discovered in the 1960s by the French company Fabriques de produits de chimie organique de Laire. The compound is claimed to possess fungicidal activity both in vitro and in vivo.

Iodetryl is fatty acid derivative patented by Russian company OOO "Nauchno-Proizvodstvennaya Firma "I. M. A." as a colloidal contrast agent.

Etalocib (LY-293111 or VML 295) is a potent and orally active leukotriene B4 receptor antagonist of the biphenylphenol class. It efficiently blocks neutrophil activation and subsequent inflammation. Additionally, it exerts antineoplastic properties through induction of cell cycle arrest and apoptosis in tumor cells. Etalocib was being developed for the treatment of inflammatory diseases and solid tumors.

Cyprodenate is a stimulant drug, developed by the French company Les Laboratoires Albert Rolland. Cyprodenate was used in the clinical practice to correct the tranquilizing action of benzodiazepine drugs. Upon administration, cyprodenate is hydrolyzed to produce dimethylethanolamine (deanol), which is a precursor of choline, and may enhance central acetylcholine formation.

Delfaprazine is an antidepressant drug, synthesized at the Spanish Centro de Investigacion, Grupo Ferrer S.A. Toxicological study in rats, rabbits, and dogs have shown that delfaprazine has less cardiotoxic side effects.

Leteprinim is the synthetic purine. It has both anti-excitotoxic neuroprotective properties and enhances the regenerative response of surviving neurons within the central nervous system. Moreover, the experiments in vitro and in vivo reveal that leteprinim can be administered after an excitotoxic event and still produce neuroprotection. This is clearly crucial for any drug designed to treat stroke or any acute central nervous system injury. Therefore, leteprinim has the pharmacological properties required by a drug intended to treat acute stroke as well as a spinal injury. It may be useful in reducing brain injury; it possesses clinical relevance for the treatment of hypoxic-ischemic encephalopathy in the newborn. Leteprinim has the therapeutic potential for use in clinical trials in the treatment of neuronal deterioration in depression.

Liarozole is an imidazole-containing compound that inhibits the cytochrome P-450-dependent metabolism of all-trans-retinoic acid (RA). Liarozole, a retinoic acid (RA) metabolism-blocking agent (RAMBA) in clinical development, has been granted orphan drug designation for congenital ichthyosis by the European Commission and the U.S. Food and Drug Administration. Later, based on the mixed results from a phase II/III trial of liarozole for the treatment of ichthyosis, Barrier decided to discontinue the development of liarozole. Liarozole displays antitumor activity against androgen-dependent and independent rat prostate carcinomas.A large phase III international study was completed comparing liarozole 300 mg twice daily with cyproterone acetate (CPA) 100 mg twice daily in a total of 321 patients with metastatic prostate cancer in relapse after first-line endocrine therapy. The results indicate that liarozole might be a possible treatment option for prostate cancer (PCA) following failure of first-line endocrine therapy.